Joseph Maly, MD
Hematology & Oncology · Louisville, KYNPI 1043502206
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $669 of the $921 with a category attached, or 72.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 22.8%. That places this record below the midpoint for hematology & oncology clinicians in KY, where the typical reported total is $4,619.
Across 32 payments — averaging $28.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$210
- Johnson & Johnson$120
- Kyowa Kirin, Inc.$120
- Amgen$100
- Pfizer$79
- Sumitomo Pharma America, Inc.$57
- plus $235 from 9 others
Across 1,365 payments — averaging $5145.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.7M
- Merck$722K
- Janssen Research & Development, LLC$526K
- Amgen$512K
- AstraZeneca$477K
- Astrazeneca UK Limited$393K
- plus $1.7M from 13 others
What the payments were for
- Food & beverage$66973%
- Education$25127%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $210 |
| Johnson & Johnson | 2 | $120 |
| Kyowa Kirin, Inc. | 1 | $120 |
| Amgen | 1 | $100 |
| Pfizer | 4 | $79 |
| Sumitomo Pharma America, Inc. | 2 | $57 |
| Bayer | 3 | $53 |
| Astellas Pharma US Inc | 2 | $45 |
| Merck | 2 | $31 |
| Genentech USA, Inc. | 1 | $27 |
| Gilead | 2 | $24 |
| Janssen Research & Development, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POTELIGEO$120
How this compares
$921 in reported general payments places this provider in the 15th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 39 | $486,068 |
| RevlimidLenalidomide | 27 | $462,930 |
| ErleadaApalutamide | 27 | $379,616 |
| LenvimaLenvatinib Mesylate | 18 | $359,968 |
| Lenalidomide | 18 | $309,548 |
| InlytaAxitinib | 17 | $299,295 |
| PomalystPomalidomide | 12 | $227,677 |
| TagrissoOsimertinib Mesylate | 13 | $213,891 |
| PromactaEltrombopag Olamine | 14 | $207,020 |
| BrukinsaZanubrutinib | 16 | $183,817 |
| InrebicFedratinib Dihydrochloride | 13 | $168,239 |
| ImbruvicaIbrutinib | 12 | $134,317 |
| OrgovyxRelugolix | 41 | $113,281 |
| Abiraterone Acetate | 23 | $84,995 |
| EliquisApixaban | 79 | $54,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $12 | $631,16940 claims |
| Johnson & JohnsonErleada, Xarelto | $120 | $398,38139 claims |
| PfizerInlyta, Eliquis | $79 | $354,03996 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $15 | $227,67712 claims |
| NovartisPromacta | $210 | $207,02014 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $57 | $113,28141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Khuda KhanLouisville$359K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Rohit KumarLouisville$31K
- Vikas SinghLouisville$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.